Tucson, AZ (PRWEB) February 01, 2015
Nuvox Pharma is pleased to announce that they have been chosen as one of six winners in the Fall 2014 Arizona Innovation Challenge, sponsored by the Arizona Commerce Authority. Read More
PHOENIX (January 20, 2015) – The Arizona Commerce Authority (ACA) today announced 10 finalists in the Fall 2014 Arizona Innovation Challenge (AIC), its bi-annual business plan competition that awards talented entrepreneurs who are solving today’s most challenging problems with technology-based solutions. Read More
NuvOx Pharma, a Tucson based biotechnology company, announced that a manuscript describing results of the Company’s product dodecafluoropentane emulsion (DDFPe) in reducing damage from myocardial infarction (MI) has been published in the journal Cardiovascular Drugs and Therapy Read More
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has received a $1Million grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma, (NCI Phase II SBIR, R44CA144817 - 02A1)". Read More
NuvOx, a Tucson, Arizona based developer of dodecafluoropentane (DDFP) based oxygen therapeutics, is adding three sites to its Phase I glioblastoma multiforme (GBM) trial of NVX108 in Australia, said Chief Business Officer David Wilson. Read More
To read more news about NuvOx Pharma, please visit our news page.
This is a comprehensive presentation of the company's Oxygen Nanotechnology Platform for treating life threatening conditions.
Dr. Unger has pioneered original research, championed the clinical translation of his research products, and founded companies in the technology-based private sector to market these products. Dr. Unger's products are routinely used in clinical diagnostic tests that impact the lives of Arizonans and improve healthcare world-wide.
NuvOx Pharma's CBO, David Wilson presents life saving innovation at AZBio Expo 2013
11th in a series of interviews from the ICUS Bubble Conference
ImportanceCardiorespiratory fitness (CRF) as assessed by formalized incremental exercise testing is [...]
ImportanceVariability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP t [...]
This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimen [...]
ImportanceOsteosarcoma of the jaws is rare and clinically distinct from osteosarcoma of the long bon [...]
The long-term prostate cancer-specific survival for patients initially managed with active surveilla [...]